Clinical Role of FDG PET in Evaluation of Cancer Patients

10.1016/0163-7258(95)00007-4

Wahl RL.Targeting glucose transporters for tumor imaging: “sweet” idea, “sour” result.J Nucl Med1996; 37:1038-1041.

Kostakoglu L, Wong JCH, Barrington SF, et al.Speech-related visualization of laryngeal muscles with fluorine-18-FDG.J Nucl Med1996; 37:1771-1773.

10.1148/radiographics.19.1.g99ja0761

10.1097/00003072-199905000-00004

10.1016/S0033-8389(03)00113-1

10.1148/radiology.202.2.9015070

10.1001/jama.285.7.914

Lowe VJ, Fletcher JW, Gobar L, et al.Prospective investigation of PET in lung nodules.J Clin Oncol1998; 16:1075-1084.

10.1148/radiology.178.3.1847239

10.1183/09031936.97.10071547

10.1148/radiology.202.2.9015071

10.1016/S1010-7940(01)00827-2

10.1183/09031936.96.09030410

10.1016/0003-4975(95)00752-0

Hicks RJ, Kalff V, MacManus MP, et al.(18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer.J Nucl Med2001; 42:1596-1604.

Hicks RJ, Kalff V, MacManus MP, et al.The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification.J Nucl Med2001; 42:1605-1613.

Ichiya Y, Kuwabara Y, Otsuka M, et al.Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography.J Nucl Med1991; 32:1655-1660.

10.1097/00000421-199608000-00020

10.1148/radiology.191.2.8153309

10.1016/S0033-8389(05)70181-0

10.1148/radiology.206.3.9494497

Mukai M, Sadahiro S, Yasuda S, et al.Preoperative evaluation by whole-body 18F-fluorodeoxyglucose positron emission tomography in patients with primary colorectal cancer.Oncol Rep2000; 7:85-87.

10.1007/BF01655817

Philips RKS, Hittinger R, Blesovsky L, Fry JS, Fielding LP.Local recurrence following curative surgery for large bowel cancer.II. The rectum and rectosigmoid. Br J Surg1984; 71:17-20.

10.1007/BF00051457

10.1148/radiology.170.2.2643134

10.1148/radiology.182.2.1732979

Findlay M, Young H, Cunningham D, et al.Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil NTS.J Clin Oncol1996; 14:700-708.

10.1007/BF02237238

Akhurst T, Larson S, Maccapinlac H, et al.Fluorodeoxyglucose (FDG) positron emission tomography (PET) immediately post-hepatic cryotherapy predicts recurrence of tumor in the liver (abstr).Proceedings of the annual meeting of the American Society of Clinical Oncology.Alexandria, Va: American Society of Clinical Oncology, 1999; 625.

10.1148/radiology.168.2.3393651

10.1007/BF02303744

Flamen P, Stroobants S, Van Cutsem E, et al.Additional value of whole-body positron emission tomography with fluorine-18-2-deoxy-D-glucose in recurrent colorectal cancer.J Clin Oncol1999; 17:894-901.

10.1046/j.1365-2168.1999.01178.x

Huebner RF, Park KC, Shepherd JE, Schwimmer J, Czernin J.A meta-analysis of the literature for whole-body FDG-PET detection of recurrent colorectal cancer.J Nucl Med2000; 41:1177-1189.

10.1016/S0748-7983(95)97046-0

Hustinx R, Paulus P, Daenen F, et al.Clinical value of positron emission tomography in the detection and staging of recurrent colorectal cancer.Gastroenterol Clin Biol1999; 23:323-329.

Boykin KN, Zibari GB, Lilien DL, McMillan RW, Aultman DF, McDonald JC.The use of FDG-positron emission tomography for the evaluation of colorectal metastases of the liver.Am Surg1999; 65:1183-1185.

10.1001/archsurg.1996.01430190025007

10.1001/archsurg.134.5.503

10.1007/BF02055166

Cohen A, Minsky BD, Schilsky RL.Cancer of the colon.In: DeVita VT, Jr, Hellman S, Rosenberg SA, eds.Cancer: principles and practice of oncology.5th ed. Philadelphia, Pa: Lippincott, 1997; 1144-1184.

10.1097/00000658-199803000-00001

Kubota R, Yamada S, Kubota K, et al.Intratumoral distribution of F18-fluoro-deoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by micro-autoradiography.J Nucl Med1992; 33:1972-1980.

Haberkorn U, Strauss LG, Dimitrakopoulou A, et al.PET studies for fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy.J Nucl Med1991; 32:1485-1490.

10.1200/JCO.20.2.388

10.1002/cncr.10336

10.1148/radiology.203.3.9169707

10.1097/00006231-199811000-00005

10.1007/s002590050275

Jerusalem G, Beguin Y, Fassotte MF, et al.Whole-body positron emission tomography using 18F-fluorodeoxyglucose for post-treatment evaluation in Hodgkin’s disease and non-Hodgkin’s lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging.Blood1999; 94:429-433.

Mainolfi C, Maurea S, Varrella P, et al.Positron emission tomography with fluorine-18-deoxyglucose in the staging and control of patients with lymphoma: comparison with clinico-radiologic assessment.Radiol Med1998; 95:98-104.

10.1080/028418699432969

Thill R, Neuerburg J, Fabry U, et al.Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma.Nuklearmedizin1997; 36:234-239. [German].

10.1007/s002590000340

10.1002/1097-0142(19951015)76:8<1460::AID-CNCR2820760825>3.0.CO;2-Y

10.1016/S0925-5710(97)00068-6

10.1258/0956462961918239

Carr R, Barrington SF, Madan B, et al.Detection of lymphoma in bone marrow by whole-body positron emission tomography.Blood1998; 91:3340-3346.

Moog F, Bangerter M, Kotzerke J, Guhlman A, Frickhofen N, Reske SN.18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow.J Clin Oncol1998; 16:603-609.

Surbone A, Longo DL, DeVita VT, et al.Residual abdominal masses in aggressive non-Hodgkin’s lymphoma after combination chemotherapy: significance and management.J Clin Oncol1988; 6:1832-1837.

10.1148/radiology.214.1.r00ja03253

10.1148/radiology.210.2.r99fe07487

Cremerius U, Fabry U, Kroll U, et al.Clinical value of FDG PET for therapy monitoring of malignant lymphoma: results of a retrospective study in 72 patients.Nuklearmedizin1999; 38:24-30. [German].

Romer W, Hanauske A, Ziegler S, et al.Positron emission tomography in non-Hodgkin’s lymphoma: assessment of chemotherapy with fluorodeoxyglucose.Blood1998; 91:4464-4471.

Spaepen K, Stroobants S, Dupont P, et al.Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first line chemotherapy in non-Hodgkin’s lymphoma: Is [18F]FDG PET a valid alternative to conventional diagnostic methods?J Clin Oncol2001; 19:414-419.

Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ.Positron emission tomography predicts prognosis after one cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease.J Nucl Med2002; 43:1018-1027.

10.1023/A:1008312726163

Rankin SC.Oesophageal cancer.In: Husband JES, Reznek RH, eds.Imaging in oncology.Oxford, England: Isis Medical Media, 1998; 93-110.

10.2214/ajr.168.2.9016218

10.1016/S0009-9260(98)80292-4

10.1148/radiographics.20.3.g00ma04713

10.1097/00000658-200103000-00002

10.1016/S0003-4975(00)02221-9

10.1136/gut.49.4.534

10.1002/1097-0142(20000901)89:5<1019::AID-CNCR11>3.0.CO;2-0

10.1002/1097-0142(20010415)91:8<1530::AID-CNCR1162>3.0.CO;2-#

Wagner JD, Schauwecker D, Davidson D, et al.Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy.J Clin Oncol1999; 17:1508-1515.

Acland KM, Healy C, Calonje E, et al.Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma.J Clin Oncol2001; 19:2674-2678.

10.1007/BF02305552

Krug B, Dietlein M, Groth W, et al.Fluor-18-fluorodeoxyglucose positron emission tomography (FDG-PET) in malignant melanoma: diagnostic comparison with conventional imaging methods.Acta Radiol2000; 41:446-452.

10.1002/(SICI)1097-0142(19980501)82:9<1664::AID-CNCR11>3.0.CO;2-2

10.1097/00000658-199805000-00017

10.1002/1097-0142(20011101)92:9<2341::AID-CNCR1581>3.0.CO;2-8

Davis JP, Maisey NM, Chevreton EB.Positron emission tomography: a useful imaging technique for otolaryngology, head and neck surgery?J Laryngol Otol1998; 112:125-127.

10.1007/s002590050293

10.1001/archotol.125.12.1322

Braams JW, Pruim J, Kole AC, et al.Detection of unknown primary head and neck tumors by positron emission tomography.Int J Oral Maxillofac Surg1997; 26:112-115.

Fischbein NJ, AAssar OS, Caputo GR, et al.Clinical utility of positron emission tomography with 18F-fluorodeoxyglucose in detecting residual/recurrent squamous cell carcinoma of the head and neck.AJNR Am J Neuroradiol1998; 19:1189-1196.

10.1148/radiology.200.1.8657901

10.1046/j.1365-2273.1997.00852.x

10.1177/000348949510400403

Greven KM, Williams DW, 3rd, Keyes JW, Jr, et al.Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation.Cancer1994; 4:1355-1359.

Lowe VJ, Boyd JH, Dunphy FR, et al.Surveillance for recurrent head and neck cancer using positron emission tomography.J Clin Oncol2000; 18:651-658.

10.1002/(SICI)1097-0347(199712)19:8<666::AID-HED4>3.0.CO;2-3

10.1288/00005537-199506000-00004

10.1148/radiology.179.3.2027989

10.1007/BF00834522

10.1097/00000658-199808000-00012

Crippa F, Agresti R, Seregni E, et al.Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer.J Nucl Med1998; 39:4-8.

10.1007/BF01249621

Avril N, Menzel M, Dose J, et al.Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis.J Nucl Med2001; 42:9-16.

Eubank WB, Mankoff DA, Takasugi J, et al.18fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer.J Clin Oncol2001; 19:3516-3523.

10.1148/radiology.203.2.9114082

Avril N, Dose J, Janicke F, et al.Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose.J Clin Oncol1996; 14:1848-1857.

Mariani G, Moresco L, Viale G, et al.Radioguided sentinel lymph node biopsy in breast cancer surgery.J Nucl Med2001; 42:1198-1215.

10.1002/jso.2930520108

Katz A, Strom EA, Buchholz TA, et al.Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation.J Clin Oncol2000; 18:2817-2827.

10.1148/radiology.210.3.r99mr43807

Bender H, Kirst J, Palmedo H, et al.Value of 18fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma.Anticancer Res1997; 17:1687-1692.

Moon DP, Maddahi J, Silverman DHS, et al.Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma.J Nucl Med1998; 39:431-435.

10.1002/1097-0142(20000615)88:12+<2927::AID-CNCR8>3.0.CO;2-V

Jansson T, Westlin JE, Ahlstrom H, et al.Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation?J Clin Oncol1995; 13:1470-1477.

Schelling M, Avril N, Nahrig J, et al.Positron emission tomography using [(18)F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer.J Clin Oncol2000; 18:1689-1695.

Mallard J, Welch AE, Hutcheon AW, et al.Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy.J Clin Oncol2000; 18:1676-1688.

Avril N, Rose CA, Schelling M, et al.Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations.J Clin Oncol2000; 18:3495-3502.

10.1097/00003072-200011000-00010